Researchers conducted a systematic review of studies assessing the cost-effectiveness or cost-utility of adjuvant immunotherapy for treating various types of cancer.

Durvalumab cost-effectiveness in limited-stage small cell lung cancer failed to meet US value thresholds despite longer ...

Sotorasib is more cost-effective in treating patients with KRAS G12C non–small cell lung cancer (NSCLC) compared with adagrasib in second- and subsequent-line treatment, accordi ...

Characterizing Opioid Prescribing Trends of Medical Oncologists From 2013 to 2019: Analysis From the Centers for Medicare & Medicaid Services Medicare Part D Prescribers Database This work supported ...

Home-based screening for anal cancer is a cost-effective way to increase screening compared to clinic-based screening, new ...

Introduction Many neonatal deaths are avoidable using existing low-cost evidence-based interventions. This study evaluated ...

Launch prices often differ from actual prices due to discounts, complicating comparisons with value-based prices from cost-effectiveness analyses. Conventional cost-effectiveness analyses may overlook ...

As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Efanesoctocog alfa prophylaxis is conventionally cost-ineffective compared with standard factor VIII ...